The jury in the second Risperdal mass-tort case in Philadelphia, while finding that Janssen Pharmaceuticals failed to warn about the risk of male breast growth from the drug, determined that the drug did not cause the plaintiff’s gynecomastia.
On March 20, the 12-member jury returned its verdict in favor of Janssen in Philadelphia Court of Common Pleas Judge Victor DiNubile Jr.’s courtroom. Ten out of the 12 agreed that Janssen failed to warn about the risks of gynecomastia in off-label pediatric use while 11 of the 12 determined the antipsychotic Risperdal did not cause plaintiff William Cirba’s breast growth. The jurors deliberated for roughly a day after a month of trial.
